Oseltamivir for the Treatment of H1N1 Influenza during Pregnancy

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 4, 2015, Pages 403-405

  Beigi, R H ^a,b   Pillai, V C ^c   Venkataramanan, R ^b,c   Caritis, S N ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

ADVERSE OUTCOME; ARTICLE; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ELIMINATION HALF-LIFE; FEMALE; FETUS DEVELOPMENT; FETUS GROWTH; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; HUMAN; INFLUENZA A (H1N1); KIDNEY TUBULE EXCRETION; MAXIMUM PLASMA CONCENTRATION; PLACENTA PERFUSION; PREGNANCY; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RENAL CLEARANCE; SEASONAL INFLUENZA; THIRD TRIMESTER PREGNANCY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; METABOLISM; PATHOGENICITY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; ENZYME INHIBITORS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84952775611     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.179     Document Type: Article

References (17)

1. Beigi, R.H. Prevention and management of influenza in pregnancy. Obstet. Gynecol. Clin. North Am. 41, 535-546 (2014).
2. Dutkowski, R. et al. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 26, 787-801 (2003).
3. He, G., Massarella, J. & Ward, P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37, 471-484 (1999).
4. Anderson, G.D. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet. 44, 989-1008 (2005).
5. Beigi, R.H. et al. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am. J. Obstet. Gynecol. 204, S84-88 (2011).
6. Pillai, V.C. et al. Population pharmacokinetics of oseltamivir in nonpregnant and pregnant women. Br. J. Clin. Pharmacol. (2015); e-pub ahead of print. doi: 10.1111/bcp.12691.
7. Greer, L.G. et al. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am. J. Obstet. Gynecol. 204, S89-S93 (2011).
8. Hill, G. et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretioncorrelation of in vivo and in vitro studies. Drug Metab. Dispos. 30, 13-19 (2002).
9. Andrew, M.A. et al. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin. Pharmacol. Ther. 81, 547-556 (2007).
10. Donner, B., Niranjan, V. & Hoffmann, G. Safety of oseltamivir in pregnancy: a review of preclinical and clinical data. Drug Saf. 33, 631-642 (2010).
11. Tanaka, T., Nakajima, K., Murashima, A., Garcia-Bournissen, F. & Koren, G. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breasfeeding women. CMAJ 181, 55-58 (2009).
12. Greer, L.G. et al. Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications. Obstet. Gynecol. 115, 711-716 (2010).
13. Xie, H.Y. et al. Infant outcomes among pregnant women who used oseltamivir for treatment of influenza during the H1N1 epidemic. Am. J. Obstet. Gynecol. 208, 293.e1-7 (2013).
14. Saito, S. et al. Outcomes of infants exposed to oseltamivir or zanamivir in utero during pandemic (H1N1) 2009. Am. J. Obstet. Gynecol. 209, 130.e1-9 (2013).
15. Meijer, W.J. et al. Oseltamivir and its active metabolite cross the placenta at significant levels. Clin. Infect. Dis. 54, 1676-1677 (2012).
16. Nanovskaya, T.N., Patrikeeva, S., Zhan, Y., Hankins, G.D. & Ahmed, M.S. Transplacental transfer of oseltamivir carboxylate. J. Matern. Fetal Neonatal. Med. 25, 2312-2315 (2012).
17. McSharry, J.J., Weng, Q., Brown, A., Kulaway, R. & Drusano, G.L. Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob. Agents Chemother. 53, 2375-2381 (2009).